Loading
A phase 2 trial of IBI343, Gemcitabine in pancreatic ductal adenocarcinoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors is a phase 2 interventional study registered as NCT07483554 by Innovent Biologics (Suzhou) Co. Ltd., with 389 participants planned, started 2026-04-20 and due to reach its primary completion in 2028-03-31. Interventions recorded: IBI343,Gemcitabine, Albumin-bound Paclitaxel. Conditions listed: CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IBI343, Innovent Biologics, Pancreatic ductal adenocarcinoma.
Shares IBI343, Gemcitabine.
Shares Innovent Biologics, Gemcitabine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/